Your session is about to expire
← Back to Search
Cancer Vaccine
Arm C (Part 1) for Melanoma (MEL60 Trial)
Phase 1 & 2
Waitlist Available
Led By Craig L Slingluff, Jr., M.D.
Research Sponsored by Craig L Slingluff, Jr
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically or cytologically proven Stage IIB - IV melanoma rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration.
Patients may have had melanoma from a cutaneous, mucosal or unknown primary site
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
MEL60 Trial Summary
The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any changes in your immune system.
Eligible Conditions
- Melanoma
MEL60 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMEL60 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Treatment-related Adverse Events Per Study Arm
T Cell Response in Peripheral Blood Over Duration of Study Participation
Secondary outcome measures
T Cell Response and Function in Peripheral Blood
MEL60 Trial Design
8Treatment groups
Experimental Treatment
Group I: Arm G(Part 1)Experimental Treatment4 Interventions
Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Group II: Arm F (Part 1)Experimental Treatment3 Interventions
Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Group III: Arm E2Experimental Treatment3 Interventions
Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Group IV: Arm E (Part 1)Experimental Treatment3 Interventions
Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Group V: Arm D (Part 1)Experimental Treatment3 Interventions
Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Group VI: Arm C (Part 1)Experimental Treatment2 Interventions
Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after the vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Group VII: Arm B (Part 1)Experimental Treatment2 Interventions
Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Group VIII: Arm A (Part 1)Experimental Treatment2 Interventions
Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Peptide Vaccine (LPV7) + Tetanus peptide
2014
Completed Phase 2
~50
Find a Location
Who is running the clinical trial?
Craig L Slingluff, JrLead Sponsor
23 Previous Clinical Trials
696 Total Patients Enrolled
18 Trials studying Melanoma
591 Patients Enrolled for Melanoma
University of VirginiaOTHER
752 Previous Clinical Trials
1,239,606 Total Patients Enrolled
14 Trials studying Melanoma
887 Patients Enrolled for Melanoma
Craig L Slingluff, Jr., M.D.Principal InvestigatorUniversity of Virginia
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger